Advancements in Protein Degradation for Cancer Therapy

Abstract

The continuous pursuit of novel therapeutic approaches to modulate biological processes and combat diseases such as cancer has led to significant advancements in protein degradation. This Patent Highlight reviews three recent patents introducing innovative compositions and methods to enhance enzyme activity and target protein degradation. These patents present groundbreaking advancements in the development of glutarimide-containing compounds and Protein−Protein Interaction Targeted Chimeras (PPI-TACs) aimed at improving therapeutic interventions' efficacy, selectivity, and stability. Important Compound Classes. Titles. Compounds; Glutarimide-Containing Pan-KRAS Mutant Degrader Compounds and Uses Thereof; and Glutarimide-Containing KRAS Mutant Degrader Compounds and Uses Thereof Patent Publication Numbers. WO 2024/115890 A1 (URL: https://patentscope.wipo.int/search/en/detail. jsf?docId=WO2024115890&_cid=P20-LX7AKU-61046-4); WO 2024/118966 A1 (URL: https://patentscope.wipo.int/ search/en/detail.jsf?docId=WO2024118966&_cid=P20-LX7AKU-61046-5); and WO 2024/118960 A1 (URL: https://patentscope.wipo.int/ search/en/detail.jsf?docId=WO2024118960&_cid=P20-LX7AKU-61046-3)